These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27785725)

  • 1. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
    Zhao Q; Xia N
    Sci China Life Sci; 2016 Nov; 59(11):1198-1201. PubMed ID: 27785725
    [No Abstract]   [Full Text] [Related]  

  • 2. Bringing the Hepatitis C Virus to Life.
    Cell; 2016 Sep; 167(1):39-42. PubMed ID: 27634322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus-From Discovery to Cure: The 2016 Lasker-DeBakey Clinical Medical Research Award.
    Bartenschlager RF; Rice CM; Sofia MJ
    JAMA; 2016 Sep; 316(12):1254-5. PubMed ID: 27623041
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis C Virus: From Obscurity to the Lasker.
    Liang TJ
    Gastroenterology; 2016 Dec; 151(6):1052-1053. PubMed ID: 27765691
    [No Abstract]   [Full Text] [Related]  

  • 5. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
    Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
    Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioneering a Global Cure for Chronic Hepatitis C Virus Infection.
    Vilarinho S; Lifton RP
    Cell; 2016 Sep; 167(1):12-15. PubMed ID: 27634325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 9. HCV research and anti-HCV drug discovery: toward the next generation.
    Wakita T
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening.
    Hao W; Herlihy KJ; Zhang NJ; Fuhrman SA; Doan C; Patick AK; Duggal R
    Antimicrob Agents Chemother; 2007 Jan; 51(1):95-102. PubMed ID: 17060518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the role of sofosbuvir in treating hepatitis C infection?
    Carey L
    JAAPA; 2015 Feb; 28(2):16-9. PubMed ID: 25621961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase.
    Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Courtney-Smith M; Brancale A
    Eur J Med Chem; 2017 Jan; 125():1115-1131. PubMed ID: 27810598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus entry.
    Zeisel MB; Felmlee DJ; Baumert TF
    Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in hepatitis C: what is coming in the next 5 years?
    Locarnini SA; Bartholomeusz A
    J Gastroenterol Hepatol; 2002 Apr; 17(4):442-7. PubMed ID: 11982725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Subgenomic replications of hepatitis C virus (HCV): new possibilities for hepatitis C prophylaxis and treatment].
    Puig-Basagoiti F; Sáiz JC
    Gastroenterol Hepatol; 2001 Dec; 24(10):506-10. PubMed ID: 11730621
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries.
    Khan H; Paeshuyse J; Murad S; Neyts J
    Antiviral Res; 2016 Jan; 125():43-5. PubMed ID: 26593977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular virology of hepatitis C].
    Moradpour D; Brass V; Gosert R; Wölk B; Blum HE
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2247-53. PubMed ID: 12564041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
    Bourlière M; Adhoute X; Ansaldi C; Oules V; Benali S; Portal I; Castellani P; Halfon P
    Expert Rev Gastroenterol Hepatol; 2015; 9(12):1483-94. PubMed ID: 26595560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.